Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
- PMID: 16968952
- DOI: 10.1124/pr.58.3.10
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Erratum in
- Pharmacol Rev. 2007 Mar;59(1):124
Abstract
The median-effect equation derived from the mass-action law principle at equilibrium-steady state via mathematical induction and deduction for different reaction sequences and mechanisms and different types of inhibition has been shown to be the unified theory for the Michaelis-Menten equation, Hill equation, Henderson-Hasselbalch equation, and Scatchard equation. It is shown that dose and effect are interchangeable via defined parameters. This general equation for the single drug effect has been extended to the multiple drug effect equation for n drugs. These equations provide the theoretical basis for the combination index (CI)-isobologram equation that allows quantitative determination of drug interactions, where CI < 1, = 1, and > 1 indicate synergism, additive effect, and antagonism, respectively. Based on these algorithms, computer software has been developed to allow automated simulation of synergism and antagonism at all dose or effect levels. It displays the dose-effect curve, median-effect plot, combination index plot, isobologram, dose-reduction index plot, and polygonogram for in vitro or in vivo studies. This theoretical development, experimental design, and computerized data analysis have facilitated dose-effect analysis for single drug evaluation or carcinogen and radiation risk assessment, as well as for drug or other entity combinations in a vast field of disciplines of biomedical sciences. In this review, selected examples of applications are given, and step-by-step examples of experimental designs and real data analysis are also illustrated. The merging of the mass-action law principle with mathematical induction-deduction has been proven to be a unique and effective scientific method for general theory development. The median-effect principle and its mass-action law based computer software are gaining increased applications in biomedical sciences, from how to effectively evaluate a single compound or entity to how to beneficially use multiple drugs or modalities in combination therapies.
Similar articles
-
Drug combination studies and their synergy quantification using the Chou-Talalay method.Cancer Res. 2010 Jan 15;70(2):440-6. doi: 10.1158/0008-5472.CAN-09-1947. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068163
-
Preclinical versus clinical drug combination studies.Leuk Lymphoma. 2008 Nov;49(11):2059-80. doi: 10.1080/10428190802353591. Leuk Lymphoma. 2008. PMID: 19021049 Review.
-
The mass-action law based algorithms for quantitative econo-green bio-research.Integr Biol (Camb). 2011 May;3(5):548-59. doi: 10.1039/c0ib00130a. Epub 2011 Mar 14. Integr Biol (Camb). 2011. PMID: 21403972
-
The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.Am J Cancer Res. 2011;1(7):925-54. Epub 2011 Aug 5. Am J Cancer Res. 2011. PMID: 22016837 Free PMC article.
-
Rational approach to the clinical protocol design for drug combinations: a review.Acta Paediatr Taiwan. 2000 Nov-Dec;41(6):294-302. Acta Paediatr Taiwan. 2000. PMID: 11198934 Review.
Cited by
-
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.Blood Cancer J. 2021 Mar 13;11(3):57. doi: 10.1038/s41408-021-00436-0. Blood Cancer J. 2021. PMID: 33714981 Free PMC article.
-
PTH1 receptor is involved in mediating cellular response to long-chain polyunsaturated fatty acids.PLoS One. 2012;7(12):e52583. doi: 10.1371/journal.pone.0052583. Epub 2012 Dec 27. PLoS One. 2012. PMID: 23300710 Free PMC article.
-
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.J Transl Med. 2024 Jul 9;22(1):641. doi: 10.1186/s12967-024-05453-8. J Transl Med. 2024. PMID: 38982548 Free PMC article.
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.Sci Rep. 2016 Sep 13;6:32992. doi: 10.1038/srep32992. Sci Rep. 2016. PMID: 27623107 Free PMC article.
-
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.Oncogene. 2020 Oct;39(44):6856-6870. doi: 10.1038/s41388-020-01465-y. Epub 2020 Sep 25. Oncogene. 2020. PMID: 32978523 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources